RYTARY Drug Patent Profile
✉ Email this page to a colleague
When do Rytary patents expire, and what generic alternatives are available?
Rytary is a drug marketed by Impax and is included in one NDA. There are eight patents protecting this drug and two Paragraph IV challenges.
This drug has twenty-five patent family members in twelve countries.
The generic ingredient in RYTARY is carbidopa; levodopa. There are eighteen drug master file entries for this compound. Thirty-five suppliers are listed for this compound. Additional details are available on the carbidopa; levodopa profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Rytary
A generic version of RYTARY was approved as carbidopa; levodopa by DR REDDYS LABS SA on August 28th, 1992.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for RYTARY?
- What are the global sales for RYTARY?
- What is Average Wholesale Price for RYTARY?
Summary for RYTARY
| International Patents: | 25 |
| US Patents: | 8 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 7 |
| Clinical Trials: | 1 |
| Patent Applications: | 460 |
| Drug Prices: | Drug price information for RYTARY |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for RYTARY |
| What excipients (inactive ingredients) are in RYTARY? | RYTARY excipients list |
| DailyMed Link: | RYTARY at DailyMed |
Recent Clinical Trials for RYTARY
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Northwestern University | Phase 2 |
| Northwestern Medical Group | Phase 2 |
| National Institutes of Health (NIH) | Phase 2 |
Pharmacology for RYTARY
| Drug Class | Aromatic Amino Acid |
Paragraph IV (Patent) Challenges for RYTARY
| Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
|---|---|---|---|---|---|---|
| RYTARY | Extended-release Capsules | carbidopa; levodopa | 23.75 mg/95 mg, 36.25 mg/145 mg, 48.75 mg/195 mg | 203312 | 1 | 2015-06-24 |
| RYTARY | Extended-release Capsules | carbidopa; levodopa | 61.25 mg/245 mg | 203312 | 1 | 2015-06-10 |
US Patents and Regulatory Information for RYTARY
RYTARY is protected by fifteen US patents.
Patents protecting RYTARY
Controlled release formulations of levodopa and uses thereof
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF PARKINSON'S DISEASE
Controlled release formulations of levodopa and uses thereof
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF PARKINSON'S DISEASE, POST-ENCEPHALITIC PARKINSONISM, AND PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION OR MANGANESE INTOXICATION
Controlled release formulations of levodopa and uses thereof
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF PARKINSON'S DISEASE, POST-ENCEPHALITIC PARKINSONISM, AND PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION OR MANGANESE INTOXICATION
Controlled release formulations of levodopa and uses thereof
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF POST-ENCEPHALITIC PARKINSONISM
Controlled release formulations of levodopa and uses thereof
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF POST-ENCEPHALITIC PARKINSONISM, AND PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION OR MANGANESE INTOXICATION
Controlled release formulations of levodopa and uses thereof
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION OR MANGANESE INTOXICATION
Controlled release formulations of levodopa and uses thereof
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF PARKINSON'S DISEASE
Controlled release formulations of levodopa and uses thereof
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF PARKINSON'S DISEASE
Controlled release formulations of levodopa and uses thereof
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF PARKINSON'S DISEASE, POST-ENCEPHALITIC PARKINSONISM, AND PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION OR MANGANESE INTOXICATION
Controlled release formulations of levodopa and uses thereof
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF PARKINSON'S DISEASE, POST-ENCEPHALITIC PARKINSONISM, AND PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION OR MANGANESE INTOXICATION
Controlled release formulations of levodopa and uses thereof
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: METHOD OF PROVIDING A THERAPEUTICALLY EFFECTIVE AND STABLE MEDIAN BLOOD PLASMA LEVEL OF LEVODOPA
Controlled release formulations of levodopa and uses thereof
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Controlled release formulations of levodopa and uses thereof
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF PARKINSON'S DISEASE
Controlled release formulations of levodopa and uses thereof
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF PARKINSON'S DISEASE
Controlled release formulations of levodopa and uses thereof
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF PARKINSON'S DISEASE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Impax | RYTARY | carbidopa; levodopa | CAPSULE, EXTENDED RELEASE;ORAL | 203312-003 | Jan 7, 2015 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Impax | RYTARY | carbidopa; levodopa | CAPSULE, EXTENDED RELEASE;ORAL | 203312-004 | Jan 7, 2015 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Impax | RYTARY | carbidopa; levodopa | CAPSULE, EXTENDED RELEASE;ORAL | 203312-003 | Jan 7, 2015 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Impax | RYTARY | carbidopa; levodopa | CAPSULE, EXTENDED RELEASE;ORAL | 203312-004 | Jan 7, 2015 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Impax | RYTARY | carbidopa; levodopa | CAPSULE, EXTENDED RELEASE;ORAL | 203312-003 | Jan 7, 2015 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Impax | RYTARY | carbidopa; levodopa | CAPSULE, EXTENDED RELEASE;ORAL | 203312-001 | Jan 7, 2015 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for RYTARY
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Impax | RYTARY | carbidopa; levodopa | CAPSULE, EXTENDED RELEASE;ORAL | 203312-001 | Jan 7, 2015 | ⤷ Sign Up | ⤷ Sign Up |
| Impax | RYTARY | carbidopa; levodopa | CAPSULE, EXTENDED RELEASE;ORAL | 203312-003 | Jan 7, 2015 | ⤷ Sign Up | ⤷ Sign Up |
| Impax | RYTARY | carbidopa; levodopa | CAPSULE, EXTENDED RELEASE;ORAL | 203312-004 | Jan 7, 2015 | ⤷ Sign Up | ⤷ Sign Up |
| Impax | RYTARY | carbidopa; levodopa | CAPSULE, EXTENDED RELEASE;ORAL | 203312-002 | Jan 7, 2015 | ⤷ Sign Up | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
EU/EMA Drug Approvals for RYTARY
| Company | Drugname | Inn | Product Number / Indication | Status | Generic | Biosimilar | Orphan | Marketing Authorisation | Marketing Refusal |
|---|---|---|---|---|---|---|---|---|---|
| Amneal Pharma Europe Ltd | Numient | levodopa, carbidopa | EMEA/H/C/002611 Symptomatic treatment of adult patients with Parkinson’s disease |
Withdrawn | no | no | no | 2015-11-19 | |
| >Company | >Drugname | >Inn | >Product Number / Indication | >Status | >Generic | >Biosimilar | >Orphan | >Marketing Authorisation | >Marketing Refusal |
International Patents for RYTARY
When does loss-of-exclusivity occur for RYTARY?
Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:
Australia
Patent: 08343787
Patent: Controlled release formulations of levodopa and uses thereof
Estimated Expiration: ⤷ Sign Up
Canada
Patent: 11014
Patent: FORMULATIONS À LIBERATION CONTRÔLEE DE LEVODOPA ET LEURS UTILISATIONS (CONTROLLED RELEASE FORMULATIONS OF LEVODOPA AND USES THEREOF)
Estimated Expiration: ⤷ Sign Up
China
Patent: 1910113
Patent: Controlled release formulations of levodopa and uses thereof
Estimated Expiration: ⤷ Sign Up
European Patent Office
Patent: 34963
Patent: FORMULATIONS À LIBÉRATION CONTRÔLÉE DE LÉVODOPA ET LEURS UTILISATIONS (CONTROLLED RELEASE FORMULATIONS OF LEVODOPA AND USES THEREOF)
Estimated Expiration: ⤷ Sign Up
Israel
Patent: 6756
Patent: תערובות שחרור מבוקרות של levodopa ושימושיהן (Controlled release formulations of levodopa and uses thereof)
Estimated Expiration: ⤷ Sign Up
Patent: 8520
Patent: תערובות שחרור מבוקרות של levodopa ושמושיהן (Controlled release formulation of levodopa and uses thereof)
Estimated Expiration: ⤷ Sign Up
Patent: 3053
Patent: תערובות שחרור מבוקרות של ושמושיהן levodopa (Controlled release formulation of levodopa and uses thereof)
Estimated Expiration: ⤷ Sign Up
Japan
Patent: 83725
Estimated Expiration: ⤷ Sign Up
Patent: 33373
Estimated Expiration: ⤷ Sign Up
Patent: 28205
Estimated Expiration: ⤷ Sign Up
Patent: 11507956
Estimated Expiration: ⤷ Sign Up
Patent: 15187178
Patent: レボドパの放出制御製剤及びその使用 (CONTROLLED RELEASE FORMULATIONS OF LEVODOPA AND USES THEREOF)
Estimated Expiration: ⤷ Sign Up
Patent: 17014295
Patent: レボドパの放出制御製剤及びその使用 (CONTROLLED RELEASE FORMULATIONS OF LEVODOPA AND USES THEREOF)
Estimated Expiration: ⤷ Sign Up
Mexico
Patent: 10007207
Patent: FORMULACIONES DE LIBERACION CONTROLADA DE LEVODOPA Y USOS DE LAS MISMAS. (CONTROLLED RELEASE FORMULATIONS OF LEVODOPA AND USES THEREOF.)
Estimated Expiration: ⤷ Sign Up
New Zealand
Patent: 6870
Patent: Controlled release formulations of levodopa, carbidopa andd a caboxylic acid
Estimated Expiration: ⤷ Sign Up
Patent: 2302
Patent: Controlled release formulations of levodopa and uses thereof
Estimated Expiration: ⤷ Sign Up
South Africa
Patent: 1005309
Patent: CONTROLLED RELEASE FORMULATIONS OF LEVODOPA AND USES THEREOF
Estimated Expiration: ⤷ Sign Up
South Korea
Patent: 1451564
Estimated Expiration: ⤷ Sign Up
Patent: 1569604
Estimated Expiration: ⤷ Sign Up
Patent: 1752080
Estimated Expiration: ⤷ Sign Up
Patent: 100099731
Patent: CONTROLLED RELEASE FORMULATIONS OF LEVODOPA AND USES THEREOF
Estimated Expiration: ⤷ Sign Up
Patent: 130113533
Patent: CONTROLLED RELEASE FORMULATIONS OF LEVODOPA AND USES THEREOF
Estimated Expiration: ⤷ Sign Up
Patent: 150133854
Patent: 레보도파 방출 제어형 제제 및 이의 용도 (CONTROLLED RELEASE FORMULATIONS OF LEVODOPA AND USES THEREOF)
Estimated Expiration: ⤷ Sign Up
Spain
Patent: 04348
Estimated Expiration: ⤷ Sign Up
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
See the table below for additional patents covering RYTARY around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| European Patent Office | 2234963 | FORMULATIONS À LIBÉRATION CONTRÔLÉE DE LÉVODOPA ET LEURS UTILISATIONS (CONTROLLED RELEASE FORMULATIONS OF LEVODOPA AND USES THEREOF) | ⤷ Sign Up |
| Canada | 2711014 | FORMULATIONS À LIBERATION CONTRÔLEE DE LEVODOPA ET LEURS UTILISATIONS (CONTROLLED RELEASE FORMULATIONS OF LEVODOPA AND USES THEREOF) | ⤷ Sign Up |
| Canada | 2486859 | ASSOCIATION DE FORMES POSOLOGIQUES DE LEVODOPA/CARBIDOPA A LIBERATION IMMEDIATE ET CONTROLEE (COMBINATION IMMEDIATE RELEASE CONTROLLED RELEASE LEVODOPA/CARBIDOPA DOSAGE FORMS) | ⤷ Sign Up |
| Taiwan | 200633730 | Oral disintegrating dosage forms | ⤷ Sign Up |
| New Zealand | 586870 | Controlled release formulations of levodopa, carbidopa andd a caboxylic acid | ⤷ Sign Up |
| South Korea | 101569604 | ⤷ Sign Up | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
